Stocks · News reference

SciSparc Invests C$2.7 Million In NeuroThera Financing, Raising Stake To 44.6% Valued At ~C$30 Million

Aug 18, 2026, 12:09 PMBenzinga Newsdesk

SciSparc Invests C$2.7 million and holds approximately 44.6% of NeuroThera’s issued and outstanding common shares following the financingTEL AVIV, Israel, Aug. 18, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC)

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

SPRC TSXV:NTLX

Source: benzinga
Observed: Aug 18, 2026, 12:09 PM
Checked: Aug 18, 2026, 12:09 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 26, 2026, 12:37 PMBenzinga Newsdesk
SciSparc Adds Prof. Carmel Domshlak To Newly Established Scientific Advisory Board For AI And Cybersecurity, Effective September 1
The addition of leading AI researcher further strengthens SciSparc’s scientific and technical foundation as the Company advances its strategic focus on the Agentic AI marketTEL AVIV, Israel, Aug. 26, 2026 (GLOBE
Read original at benzinga
SPRC
BenzingaAug 24, 2026, 12:54 PMBenzinga Newsdesk
SciSparc Unit Neurothera Labs And Clearmind Medicine Publish U.S. Patent Application For A Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines For Use In Methods Of Treating Post-Traumatic Stress Disorder, Anxiety And Eating Disorders
Read original at benzinga
CMND SPRC TSXV:NTLX
BenzingaAug 18, 2026, 5:07 PMBenzinga Newsdesk
SciSparc shares are trading higher. The company announced its majority-owned subsidiary, NeuroThera Labs, has completed two tranches of non-brokered private placements, raising aggregate gross proceeds of C$5.4 million.
16.86 -1.64 [-8.86%]
Read original at benzinga
SPRC
BenzingaAug 5, 2026, 12:23 PMBenzinga Newsdesk
SciSparc's NeuroThera Labs Initiates Phase IIb Clinical Study To Evaluate SCI-110 Drug Candidate To Treat Tourette Syndrome
SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV:NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel
Read original at benzinga
SPRC TSXV:NTLX
BenzingaJul 29, 2026, 12:36 PMBenzinga Newsdesk
SciSparc's NeuroThera Labs Subsidiary Completes Internal Validation Of Quantum Sampling Workflow Developed Platform For Clinical Trials Data Analysis
Read original at benzinga
SPRC TSXV:NTLX

SciSparc Invests C$2.7 Million In NeuroThera Financing, Raising Stake To 44.6% Valued At ~C$30 Million

Connected markets

Related headlines

SciSparc Adds Prof. Carmel Domshlak To Newly Established Scientific Advisory Board For AI And Cybersecurity, Effective September 1

SciSparc Unit Neurothera Labs And Clearmind Medicine Publish U.S. Patent Application For A Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines For Use In Methods Of Treating Post-Traumatic Stress Disorder, Anxiety And Eating Disorders

SciSparc shares are trading higher. The company announced its majority-owned subsidiary, NeuroThera Labs, has completed two tranches of non-brokered private placements, raising aggregate gross proceeds of C$5.4 million.

SciSparc's NeuroThera Labs Initiates Phase IIb Clinical Study To Evaluate SCI-110 Drug Candidate To Treat Tourette Syndrome

SciSparc's NeuroThera Labs Subsidiary Completes Internal Validation Of Quantum Sampling Workflow Developed Platform For Clinical Trials Data Analysis